Innoviva Inventory Turnover Ratio 2006-2020 | INVA

Innoviva inventory turnover ratio from 2006 to 2020. Inventory turnover ratio can be defined as a ratio showing how many times a company's inventory is sold and replaced over a period.
Innoviva Inventory Turnover Ratio Historical Data
Date
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.370B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.238B 18.65
Roche Holding AG (RHHBY) Switzerland $294.553B 0.00
Pfizer (PFE) United States $213.662B 13.35
Merck (MRK) United States $204.919B 14.63
Novartis AG (NVS) Switzerland $189.756B 14.75
AbbVie (ABBV) United States $163.988B 9.99
Novo Nordisk (NVO) Denmark $152.214B 24.77
Eli Lilly (LLY) United States $146.273B 22.33
AstraZeneca (AZN) United Kingdom $145.417B 28.27
Sanofi (SNY) $128.988B 15.33
GlaxoSmithKline (GSK) United Kingdom $102.323B 13.42
Bayer (BAYRY) Germany $61.403B 8.85
H Lundbeck (HLUYY) Denmark $7.388B 0.00